GT Biopharma
GTBP

$2.18

3.11%

Market Cap: $4.87M

About: GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Employees: 2

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10,801% more capital invested

Capital invested by funds: $350K [Q1] → $38.1M (+$37.8M) [Q2]

44.52% more ownership

Funds ownership: 5.49% [Q1] → 50.01% (+44.52%) [Q2]

0% more funds holding

Funds holding: 17 [Q1] → 17 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GTBP.

See Analyst Rankings

Financial journalist opinion

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company's common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 740,000 shares of common stock. The warrants have an exercise price of $4.35 per share, will be exercisable immediately and will have a term of five years following the date of issuance. The closing of the offering is expected to occur on or about May 23, 2024, subject to the satisfaction of customary closing conditions.

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn't been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company.

What made GT Biopharma stock more than double on Monday?

Why Is GT Biopharma (GTBP) Stock Up 143% Today?

GT Biopharma (NASDAQ: GTBP ) stock is soaring higher on Monday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 10.6 million shares of GTBP stock changing hands as of this writing.

Why Is GT Biopharma (GTBP) Stock Up 143% Today?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced first quarter 2024 financial results for the period ended March 31, 2024.

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol “GTBP” and will begin trading on a post-split basis at the market open on February 5, 2024. The CUSIP number for the common stock following the reverse stock split will be 36254L 308. The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended GT Biopharma stockholders entitled to vote at the Company's 2023 Special Meeting of Stockholders (the “Special Meeting”) to vote “ FOR ” Proposal items number 1 and 2. If approved, Proposal No. 1. will provide the Company's Board of Directors (the “Board”) with the option to implement a reverse stock split of the Company's issued and outstanding common stock (the “Reverse Split”), if deemed necessary in the future, to maintain the Company's listing on the Nasdaq Capital Market (“Nasdaq”).

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

See News Rankings